Graul Ann I, Revel Laura, Barrionuevo Meritxell, Cruces Elisabet, Rosa Esmeralda, Verges Clara, Lupone Becky, Diaz Nuria, Castaner Rosa
Drug News Perspect. 2009 Jan-Feb;22(1):7-29. doi: 10.1358/dnp.2009.22.1.1303754.
This annual article presents new drugs and biologics that were launched or approved for the first time during the previous year. In 2008, 31 new medicines-this figure includes both drugs and biologics for therapeutic use as well as new diagnostic agents-reached their first markets. Line extensions (new indications, new formulations and new combinations of previously marketed products) accounted for more than one-third of the new medicines launched in 2008. In addition to providing an overview of all drugs and biologics launched or approved for the first time ever in the previous year, this article will also review in further depth the first-in-class drugs launched for the first time last year, providing a better understanding of their novel mechanisms of action; an analysis of the discovery and development periods for the year's new products; and a comprehensive overview of drug repositioning as a strategy for extending the life spans of medicines. We also provide a brief glimpse at selected drugs and biologics which could reach their first markets in the foreseeable future.
本年度文章介绍了上一年首次上市或获批的新药和生物制品。2008年，31种新药（这一数字包括治疗用药物和生物制品以及新的诊断试剂）首次进入市场。产品线延伸（先前上市产品的新适应症、新剂型和新组合）占2008年推出的新药的三分之一以上。除了概述上一年首次上市或获批的所有药物和生物制品外，本文还将更深入地回顾去年首次推出的同类首创药物，以便更好地了解其新颖的作用机制；分析当年新产品的发现和开发周期；以及全面概述药物重新定位作为延长药物寿命的一种策略。我们还简要介绍了一些在可预见的未来可能首次进入市场的选定药物和生物制品。
